However, among 163 carriers of pathogenic somatic TP53 variants in our study whose tumor LOH status was discernible, we identified that some tumors exhibited loss of DDR-related genes, such as ERCC6, PTEN, RIF1, POLD2, PRKDA, SMARCA4, TDG, TTK and VWHAE. In these cases, though somatic mutations in HR pathway might not be detected, the aberrations of DDR pathway might facilitate tumor responding to Pt-based chemotherapy. The gene discussed is ERCC6; the disease is neoplasm.